ViƱa, Analyn T.
HRN: 21-41-51 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/31/2022
CEFUROXIME 1.5GM (VIAL)
05/31/2022
06/07/2022
IV
1.5g
Q8
UTI; Thickly MSAF; G4P4
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes